The Impact of Versatile Macrophage Functions on Acute Kidney Injury and Its Outcomes

Jea-Hyun Baek*

Research & Early Development, Biogen Inc., Cambridge, MA, United States

Acute kidney injury (AKI) is a common and devastating clinical condition with a high morbidity and mortality rate and is associated with a rapid decline of kidney function mostly resulting from the injury of proximal tubules. AKI is typically accompanied by inflammation and immune activation and involves macrophages (Mφ) from the beginning: The inflamed kidney recruits “classically” activated (M1) Mφ, which are initially poised to destroy potential pathogens, exacerbating inflammation. Of note, they soon turn into “alternatively” activated (M2) Mφ and promote immunosuppression and tissue regeneration. Based on their roles in kidney recovery, there is a growing interest to use M2 Mφ and Mφ-modulating agents therapeutically against AKI. However, it is pertinent to note that the clinical translation of Mφ-based therapies needs to be critically reviewed and questioned since Mφ are functionally plastic with versatile roles in AKI and some Mφ functions are detrimental to the kidney during AKI. In this review, we discuss the current state of knowledge on the biology of different Mφ subtypes during AKI and, especially, on their role in AKI and assess the impact of versatile Mφ functions on AKI based on the findings from translational AKI studies.

Keywords: macrophage, acute kidney damage, fibrosis, macrophage depletion, chronic kidney disease

INTRODUCTION

Severe AKI is a clinical condition closely linked with a high morbidity and mortality rate (Zuk and Bonventre, 2016). AKI manifests as a rapid decline of kidney function and is associated with CKD (Chawla et al., 2014; Fiorentino et al., 2018). AKI mostly results from the injury of proximal tubules and is accompanied by inflammation and immune activation (Zuk and Bonventre, 2019). Thereby, distinct Mφ subtypes are involved across different stages of AKI (Huen and Cantley, 2017; Chen et al., 2019): (1) “Classically” activated (M1) Mφ, which are poised to destroy potential pathogens, are recruited to the inflamed tissue and exacerbate inflammation in the initial stage of AKI; (2) “alternatively” activated (M2) Mφ predominate in the injured tissue during the resolution phase of AKI and mediate immunosuppression and tissue regeneration; and (3) the last-mentioned also play

Abbreviations: AKI, acute kidney injury; CKD, chronic kidney disease; CLP, cecal ligation and puncture; CSF, colony-stimulating factor; DAMPs, damage-associated molecular patterns; DT, diphtheria toxin; (i)DTR, (inducible) diphtheria toxin receptor; ECM, extracellular matrix; IRI, ischemia-reperfusion injury/surgery; LPS, lipopolysaccharide; Mφ, macrophage(s); PAMPs, pathogen-associated molecular patterns; PDGF, platelet-derived growth factor(s); PRR, pathogen recognition receptor(s); RA, retinoic acid; Th, T helper type; TLR, toll-like receptor; UUO, unilateral ureteral obstruction.
a role in the transition of AKI to CKD. As M2 Mφ are found to be protective against AKI, there is a growing interest to use M2 Mφ and Mφ-modulating agents as therapeutic tools to treat patients with AKI (Chen et al., 2019). Whilst valuing its immense therapeutic potential, it is to acknowledge that the clinical translation of Mφ-based therapies needs to be critically reviewed and questioned, especially since Mφ act like double-edged swords being both beneficial and harmful to the injured tissue (Figure 1) (Braga et al., 2015). In this review, we discuss the current state of knowledge on the biology of different Mφ subtypes during AKI and on the impact of global Mφ and Mφ subtypes on AKI based on the findings from in situ Mφ depletion studies. At the end, we outline Mφ-based therapeutic strategies for the treatment of AKI.

KIDNEY Mφ IN STEADY STATE AND INFLAMMATION

Mφ are, as their name implies: [Greek: macrophage = μακρός (large) + φαγέω (to eat)], cells highly specialized in phagocytosis, belonging to the mononuclear phagocytic system (MPS). They reside in virtually all organs and orchestrate tissue homeostasis and inflammation, being capable of both inducing and suppressing immune responses as well as promoting tissue repair. Mφ are also the most abundant leukocytes in the resting and inflamed kidney, maintained by two main Mφ survival factors, CSF-1 and interleukin-34 (IL-34), primarily expressed by tubular epithelial cells (Isbel et al., 2001; Menke et al., 2009; Zhang et al., 2012; Baek et al., 2015). Both cytokines are further up-regulated during renal inflammation and account for Mφ expansion of in the kidney tissue (Baek et al., 2015). CSF-1 and IL-34 both signal through the CSF-1 receptor (CSF-1R), whereas the signaling via CSF-1R is the key pathway for Mφ proliferation, differentiation, and survival (Baek et al., 2015). In addition to CSF-1R, IL-34 activates another receptor, which is receptor-type tyrosine-protein phosphatase zeta (PTP-ζ), (Nandi et al., 2013). However, there is so far no evidence that PTP-ζ is expressed by Mφ (Baek et al., 2015).

Like Mφ in other organs, first kidney Mφ arise during organogenesis, derived from erythro-myeloid progenitors that are generated in the yolk sac before E8.5 and colonize the fetal liver of the embryo. These primitive progenitors give rise to pre-Mφ, which simultaneously populate the whole embryo from E9.5 and differentiate to fetal and perinatal tissue-specific Mφ activating tissue-dependent transcriptional machinery (Mass et al., 2016). Tissue-resident Mφ are known to renew themselves in situ throughout the lifetime of the host (Figure 2). However, Mφ arising from blood-circulating monocytes (also known as circulating Mφ precursors) are also detected in resting adult kidneys, but they turn over within 14 days and do not substitute kidney-resident Mφ unless kidney-resident Mφ niches become available (Lever et al., 2019).

In the occurrence of inflammation, additional Mφ are recruited from the blood circulation (Sere et al., 2012). Blood-circulating monocytes are attracted to the site of inflammation, where they differentiate to Mφ and clear pathogens and cellular debris (Figure 2).

Mφ exert multiple biological functions in health and disease. Most importantly, they are instrumental in both promoting and resolving inflammation, which are two contrasting features. Correspondingly, Mφ are broadly classified into two subpopulations according to their phenotype and function: So-called “classically activated” Mφ (M1) are the Mφ subpopulation inducing cytotoxicity and tissue injury; conversely, “alternatively” activated (M2) Mφ comprise the other subpopulation, which is involved in immunosuppression and tissue repair (Mills et al., 2000; Murray and Wynn, 2011). Overall, M1/M2 paradigm is a theoretical and oversimplified concept, which was firstly proposed by Mills et al. based on the observation that Mφ from mouse strains with Th 1 (e.g., C57BL/6, B10D2) and Th2 (e.g., BALB/c, DBA/2) display distinctive activation profiles differing in metabolic programs (Mills et al., 2000). Correspondingly, both Mφ phenotypes were named M1 and M2 and characterized in vitro by stimulating bone marrow or monocyte-derived Mφ with either Th1 (e.g., LPS, Interferon γ) or Th2 stimuli (e.g., IL-4, IL-10, IL-13) (Figure 3). In addition,
M2-activated Mφ are further subdivided into different groups based on the Th2 stimulus, with which Mφ are treated for M2 polarization. Of note, different M2 stimuli have distinct effects on transcriptional profiles and cellular functions of Mφ (detailed information in Murray et al., 2014; Chen et al., 2019).

One of the unique characteristics of Mφ is functional plasticity. In other words, Mφ can easily change their phenotype from one activation state to the other. Thus, in vivo Mφ are, in reality, somewhere along the continuum between the two in vitro-defined phenotypes (M1 and M2), and in vitro polarized Mφ do not fully recapitulate in vivo Mφ in pathologic conditions (Figure 3) (Geissmann et al., 2010).

As Mφ play important roles in many biological processes, their malfunction is linked to various diseases. While Mφ-mediated immune hyper-activation can lead to autoimmune and inflammatory diseases, unregulated tissue homeostasis can promote cancer growth and organ fibrosis. Accordingly, Mφ are implicated in numerous renal diseases including lupus nephritis, glomerulonephritis as well as in AKI (Nikolic-Paterson and Atkins, 2001; Baek et al., 2018).

EXPERIMENTAL AKI MODELS

AKI is characterized by an abrupt loss of kidney function arising from different events, such as (1) sepsis/septic shock, (2) ureteral obstruction, (3) kidney ischemia, (4) hypoxia, (5) nephrotoxicity, (6) oxidative, and (7) metabolic stress. Of note, all etiologies share one common feature, which is the proximal tubular injury accompanied with inflammation and immune activation (Basile et al., 2012; Chevalier, 2016; Xu and Han, 2016). Proximal tubular injury can be acutely detrimental to the kidney as well as to the whole organism by impairing key kidney functions, such as reabsorption and secretion, and can lead to long-term problems (e.g., transitioning to CKD and increased risk of CKD and eventual death even after a complete recovery) (Bucaloiu et al., 2012; Jones et al., 2012). Of note, proximal tubules are highly vulnerable to injuries due to the high demand of oxygen consumption, which is required for multiple transport processes, and a relative paucity of endogenous antioxidant defenses (Chevalier, 2016). Thus, proximal tubules are the major target of AKI, and, in line with this, clinically relevant studies demonstrate that molecular targeting of the proximal tubule is sufficient to induce AKI and its transition to CKD (Chevalier, 2016).

For studying AKI, a number of experimental techniques have been developed to directly or indirectly target the kidney, including: (1) surgical approaches – UUO, IRI, CLP (via sepsis), etc.; (2) systemic administration of drugs or toxins inducing nephrotoxicity – injection of cisplatin, glycerol (via rhabdomyolysis), bacterial LPS (via sepsis) etc. (Ramesh and Ranganathan, 2014; Ortiz et al., 2015; Rabb et al., 2016; Bao et al., 2018; Johnson and Zager, 2018); and (3) selective depletion of proximal tubules in genetically modified mice, i.e., injecting mice with DT, which express human DT receptor (DTR) on proximal tubules – Ggt1-DTR (Zhang et al., 2012, 2017; Wang et al., 2015), Ndrgr1-CreERT2-DTR (Takaori et al., 2016), etc. Importantly, molecular mechanisms of AKI progression may differ depending on the type of insult to the proximal tubule. In effect, methods using (1) septic versus aseptic approaches, (2) systemic versus local, and (3) mild versus severe insults may involve different signaling pathways. This point is well illustrated in studies showing that the nucleotide-binding oligomerization domain, leucine rich repeat and pyrin domain containing 3 (NLRP3) inflammasome pathway is activated in ischemic, but not cisplatin-induced AKI (Kim et al., 2013). As AKI is a major risk factor for CKD progression, CKD is often assessed as a readout for AKI, and experimental AKI models are commonly utilized in the CKD research (detailed information in Tanaka et al., 2014; Chou et al., 2017; Fiorentino et al., 2018). Of note, not all experimental AKI are irreversible and lead to CKD (Chawla et al., 2011; Basile et al., 2012). Overall, it is important to determine the appropriate AKI model depending on the question being asked by giving consideration to the possibility that findings may not be transferable between experimental models. While designing the experiment, we need to consider the pathophysiology of mouse models and the mode of action of tested drugs and specify the model type, functional determination and time course of tissue collection (Ramesh and Ranganathan, 2014). Limitations and pitfalls of animal AKI models as well as the differences between AKI models have been recently described in several reviews. For a comparative overview of the various AKI animal models, please refer to the reviews: Ortiz et al. (2015), Rabb et al. (2016), and Bao et al. (2018).

Mφ IN AKI

Infiltrating Mφ in the Initial Phase of AKI

In experimental AKI models, blood-circulating Ly6Chigh monocytes are recruited to the inflamed kidney as early as within 1 h (Li and Okusa, 2010; Zhang et al., 2012). The migration of Ly6Chigh monocytes to the site of inflammation occurs through chemotactic mechanisms (e.g., via CCR2 and CX3CR1). Therefore, deletion or blockage of chemotaxis receptors on monocytes is found to be protective against ischemia-induced AKI in mice (Furuichi et al., 2003; Li et al., 2008; Lu et al., 2008;
Oh et al., 2008; Yang et al., 2019). Monocyte infiltration occurs in the first 48 h (Lu et al., 2008) and completely ceases before day 3 of AKI. Accordingly, studies showed that the number of Ly6C<sup>high</sup> monocytes and M1-like Mϕ drastically declines before day 3 of IRI (Lee et al., 2011; Lever et al., 2019) and CX<sub>3</sub>CRI-dependent monocyte migration is not detectable at day 3 of UUO (Peng et al., 2015). Interestingly, the peak of tubular injury [e.g., following IRI (Lee et al., 2011) and glycerol injection (Bussolati et al., 2005)] timely overlaps with the maximum presence of infiltrating monocytes, indicating a close spatial and temporal relationship between the tissue destruction and the accumulation of infiltrating monocytes.

Ly6C<sup>high</sup> monocytes differentiate into Mϕ, which are primarily skewed toward an M1 phenotype. M1 Mϕ polarization is mediated by pro-inflammatory cytokines [e.g., IFN-γ, IL-6, IL-1β, IL-17, C3, C5a, and C5b (Rabb et al., 2016)] and DAMPs [e.g., high mobility group protein B1 (HMGB1), adenosine triphosphate (ATP), uric acid, or hypomethylated DNA (Anders, 2010; McDonald et al., 2010)] released by dying cells or damaged ECM (Anders and Schaefer, 2014). Most recently, soluble epoxide hydrolase was identified as a proximal tubular factor driving M1 polarization of Mϕ in IgA nephropathy (Wang Q. et al., 2018). DAMPs activate various PRRs [e.g., TLR families (Kulkarni et al., 2014; Leaf et al., 2017), NLRP3 and purinergic receptors (Anders and Schaefer, 2014)] on Mϕ and parenchymal cells (Leaf et al., 2017). The importance of DAMPs in inducing innate immune responses is highlighted by findings that the inhibition of PRR signaling suppresses immune responses in AKI (Kim et al., 2013; Leaf et al., 2017). Similar mechanisms are known from acute injuries in other organs, corroborating that DAMPs are central to the immune activation during tissue injury (Egawa et al., 2013; Wang et al., 2014; Groves et al., 2018). Interestingly, TLR4 activation was also shown to induce the expression of IL-22 in Mϕ, which is protective against AKI accelerating kidney regeneration (Kulkarni et al., 2014). M1 polarization of infiltrating Mϕ is additionally supported by parenchymal factors [e.g., Krüppel-like factor 5 (KLF5) expressed by collecting ducts (Fujiu et al., 2011) and suppressor of cytokine signaling 3 (SOCS3) upregulated by proximal tubules in AKI (Susnik et al., 2014)]. Both KLF5 and SOCS3 promote M1 activation of Mϕ and inhibit the expansion of M2 Mϕ in AKI (Fujiu et al., 2011; Susnik et al., 2014). M1-activated Mϕ largely produce pro-inflammatory cytokines and mediators (e.g., IL-1α, IL-6, IL-12, IL-18, TNF-α, nitric oxide), in turn, exacerbating the kidney inflammation (Li and Okusa, 2010).

**Beneficial Effects of M2-Activated Mϕ in AKI**

Beneficial effects of M2-activated Mϕ in AKI are supported by many findings: (1) M2 Mϕ clear intraluminal debris (e.g., by apoptosis inhibitor of Mϕ [AIM]-dependent mechanisms) (Arai et al., 2016); (2) secrete tissue-reparative factors, which rapidly adapt to the tissue microenvironment, it is difficult to trace the development of individual Mϕ subtypes during AKI. Nevertheless, we are steadily expanding our knowledge base through genetic fate mapping studies and parabiosis experiments. Earlier fate mapping studies revealed that Ly6C<sup>high</sup> monocytes infiltrating the inflamed kidney give rise to Ly6C<sup>low</sup> and Ly6C<sup>int</sup> Mϕ, both phenotypically resembling tissue-resident Mϕ (Lin et al., 2009) (Figure 4). Several studies have shown that monocyte-derived Ly6C<sup>int</sup> and Ly6C<sup>low</sup> Mϕ populations display transcriptionally and functionally distinct M2 phenotypes, both implicated in immunosuppression and tissue regeneration. In the later stages of AKI, Ly6C<sup>low</sup> Mϕ predominate over Ly6C<sup>int</sup> Mϕ and are found to promote interstitial fibrosis (Lin et al., 2009; Clements et al., 2016; Lever et al., 2019; Yang et al., 2019) (Figure 4). More recent studies revealed that quiescent tissue-resident Mϕ remain in the tissue independently of monocyte-derived Ly6C<sup>low</sup> Mϕ (Lin et al., 2009; Zhang et al., 2012; Lever et al., 2019) and are reprogramed in AKI toward a developmental state resembling perinatal Mϕ (Schulz et al., 2012; Mass et al., 2016), which are implicated in early kidney development (Lever et al., 2019). These cells display a unique transcriptional profile complying with neither canonical M1 nor M2 nor quiescent Mϕ phenotypes during the first 3 days after IRI. Interestingly, they activate the canonical wingless-type MMTV integration site family (Wnt) signaling by expressing Wnt ligand genes and downstream intracellular signaling mediators, implying that they mediate kidney healing after AKI (Lever et al., 2019). How reprogramed kidney-resident Mϕ further develop in the later stages of AKI and whether they are related to interstitial fibrosis following AKI deserve further investigation (Figure 4).

![FIGURE 4 Schematic representation of Mϕ subtypes throughout different stages of AKI.](https://www.frontiersin.org/article/10.3389/fphys.2019.01016)

### M2 Polarization of Infiltrating Mϕ in the Resolution Phase of AKI

Inflammation following a transient insult is meant to prepare the tissue for healing. When the inflammation escalates (before day 3 of AKI), Mϕ seek to counteract overwhelming immune activation by skewing toward an immunosuppressive M2 Mϕ to restore tissue homeostasis (Figure 3) (Lee et al., 2011; Baek et al., 2015). However, this only depicts the global view of Mϕ dynamics and does not resolve how individual Mϕ subtypes change during AKI. Since Mϕ are highly plastic and...
limit cell cycle arrest (Lin et al., 2010) or apoptosis (Lin et al., 2010; Sola et al., 2011) or which support proliferation in tubular cells (Schmidt et al., 2013) [e.g., Wnt-7b (Lin et al., 2010), lipocalin-2 (Sola et al., 2011), breast regression protein 39 (BRP-39) (Schmidt et al., 2013)]; (3) secrete anti-inflammatory cytokines, which suppress effector T cells or activate regulatory T cells (e.g., IL-10, TGF-β) (Chen et al., 2019); and (4) reduce neutrophil infiltration by downregulating intracellular adhesion molecule-1 (ICAM-1) (Karasawa et al., 2015) and potentially also by sequestering the tissue damage through "cloaking" mechanisms as found in the peritoneal serosa (Uderhardt et al., 2019) etc. As M1 Mφ are converted into M2 Mφ in the resolution phase of AKI, a number of studies have focused on identifying stimuli driving Mφ phenotypic switch during AKI. These stimuli include: (1) paracrine factors released from parenchymal and immune cells; (2) systemic factors, which are released into the blood circulation; and potentially (3) (tissue micro)environmental changes [e.g., apoptotic neutrophils (Filardy et al., 2010; Lee et al., 2011), oxygen (Raggi et al., 2017), (tissue micro)environmental changes [e.g., apoptotic neutrophils (Filardy et al., 2010; Lee et al., 2011), oxygen (Raggi et al., 2017), and nutrient availability (Geeraerts et al., 2017)].

### Paracrine Factors Released by Proximal Tubules

As mentioned above, proximal tubules are the main locale of the inflammation and potent producers of cytokines in AKI. Therefore, it would not be surprising if they substantially contributed to the phenotypic switch of Mφ in AKI. In proximal tubule/Mφ co-culture experiments (proximal tubules and Mφ physically separated), quiescent proximal tubules are capable of polarizing both non- and M1-activated Mφ toward an M2 Mφ phenotype in a paracrine manner, similarly as known from mesenchymal stem cells (Lee et al., 2011; Huen et al., 2015). Unfortunately, the proximal tubular mechanisms of M2 polarization are still largely elusive, and it is also unclear whether the contribution of proximal tubules or proximal tubule-derived factors is indispensable for M2 Mφ polarization in the resolution phase of AKI. Several studies suggest that proximal tubule-derived Mφ survival factors (e.g., CSF-1, -2, IL-34) drive M2 Mφ polarization, but these results remain controversial as discussed in the following paragraph. Proximal tubule-derived factors identified to polarize Mφ toward an M2 phenotype are Wnt ligands and netrin-1, which are both upregulated during AKI (Reeves et al., 2008; Grenz et al., 2011; Ranganathan et al., 2013; Feng et al., 2018a,b). It has been shown that the blockade of Wnt/β-catenin signaling diminishes M2 Mφ polarization also reducing interstitial fibrosis in AKI (Feng et al., 2018a,b). Netrin-1 deficiency was found to aggravate AKI, whereas the adoptive transfer of netrin-1-treated Mφ was protective against AKI (Reeves et al., 2008; Grenz et al., 2011; Ranganathan et al., 2013). Proximal tubules also express both transforming growth factor β (TGF-β) and its receptors at high levels. While TGF-β with its pleiotropic effects acts on various cell types, it is known to polarize Mφ toward an anti-inflammatory (Wang et al., 2005) and pro-fibrotic phenotype (Braga et al., 2015). However, it is unclear how beneficial the Mφ-specific effects of TGF-β are on AKI as TGF-β can signal directly to proximal tubules and induce proximal tubular apoptosis (Nath et al., 2011; Gewin et al., 2012).

### Controversial Roles of Mφ Survival Factors in Mφ Polarization

CSF-1 and -2 are produced and up-regulated by proximal tubules during AKI. Many studies have pinpointed Mφ survival factors, CSF-1 (Menke et al., 2009; Alíkhan et al., 2011; Zhang et al., 2012; Wang et al., 2015) and -2 [also known as granulocyte-Mφ CSF (GM-CSF)] (Huen et al., 2015), as factors driving the phenotypic switch toward an M2 phenotype, but this feature of Mφ survival factors is highly controversial. CSF-1 and -2 are commonly used for generating in vitro Mφ from bone marrow or blood monocytes, both being sufficient for Mφ differentiation and maturation. Since CSF-1 and -2 mature and induce expression of distinct patterns of functional genes after a sufficient culture period, researchers have been incited to determine the polarization potential of CSF-1 and -2 and were led to propose that CSF-1 give rise to a more M2-like and CSF-2 to more M1-like expression patterns in Mφ in vitro (Lacey et al., 2012). Nevertheless, it is important to understand that the translatability of in vitro data is limited as CSF-1 and -2 show in vitro M2 polarization potential only at high concentrations (Lutz et al., 2000; Hume and MacDonald, 2012; Huen et al., 2015) while being efficient at maintaining Mφ already at low concentrations (Hamilton et al., 1988; Lutz et al., 2000; Meshikhab et al., 2014). Whereas a number of studies have claimed that both CSF-1 and -2 drive M2 skewing of Mφ in mice with AKI (Zhang et al., 2012; Huen et al., 2015; Wang et al., 2015), it was controversially found that IL-34, another ligand for CSF-1R, does not polarize Mφ in murine AKI (Baek et al., 2015) and lupus model (Wada et al., 2019), indicating that CSF-1R signaling is dispensable in M2 Mφ polarization. Supportive of this data, other studies have shown that: (1) increased CSF-1 expression in the resolution phase of AKI is not sufficient to prevent Mφ from M1 polarization when Mφ are exposed to an M1 stimulus or when they are deprived of an M2 stimulus during AKI (Fujii et al., 2011; Susnik et al., 2014; Chiba et al., 2016); (2) quiescent and M2 Mφ in the resolution phase of AKI differ in transcriptional profiles and functions (Lever et al., 2019; Yang et al., 2019); and (3) the sustained blockage of CSF-1R or the constitutive deletion of CSF-1 ameliorates AKI (Lenda et al., 2003; Ma et al., 2009; more discussion in Assessing Mφ functions by depleting Mφ section). Nevertheless, what is consistent throughout all studies (Zhang et al., 2012; Baek et al., 2015; Huen et al., 2015; Wang et al., 2015; Chiba et al., 2016) is that the deficiency in Mφ survival factors reduces the number of Mφ (including that of M2 Mφ predominating in the resolution phase of AKI). It is interesting to note that the deletion of proximal tubule CSF-1 or the blockade of CSF-2 in AKI leads to a reduction in expression of M2 Mφ-specific genes, which appears modest (<30%; except regarding Arg1 expression), which may have resulted from the altered ratio of infiltrating and kidney-resident Mφ, as blood-circulating Mφ are not affected by the deletion of proximal tubule CSF-1.
or the blockade of CSF-2 (Huen et al., 2015; Wang et al., 2015). The observation that clodronate-induced Mφ depletion increased initial AKI and reduced recovery in the absence of proximal tubule CSF-1 (Wang et al., 2015) provided additional evidence that CSF-1 is not required or sufficient for M2 Mφ polarization (also commented in Perry and Okusa, 2015). Taken together, CSF-1, -2 and IL-34 are likely not sufficient to polarize Mφ toward M2 phenotype, but promote the expansion of M2 Mφ post-AKI (Chiba et al., 2016). It would be interesting for future work to explore whether Mφ survival factors have only redundant functions and, if not, what the unique, non-overlapping, functions of these Mφ survival factors are.

### Other Factors Inducing M2 Polarization of Mφ

Th2 cytokines, IL-4, -10, and -13, are detected in the resolution phase of AKI, but they are not functionally expressed in proximal tubules (Andres-Hernando et al., 2017; Zhang et al., 2017). IL-4 and -13 are produced by Th2 T cells, basophils, mast cells, and granulocytes, whereas IL-10 is produced by regulatory T cells (Liu et al., 2011), B cells as well as Mφ, induced by prostaglandins, glucocorticoids, apoptotic cells, and G protein-coupled receptor ligands (Zhang et al., 2017). IL-10, which is part of negative feedback response to inflammation and expressed along with pro-inflammatory cytokines, is released into the local tissue and blood circulation and contributes to the suppression of AKI (Deng et al., 2001; Wan et al., 2014; Greenberg et al., 2015; Zhang et al., 2015). Circulating pentraxin-2, also known as serum amyloid P, is found to facilitate the uptake of apoptotic cells and to bind to Fcγ receptors by opsonizing apoptotic cells. This process triggers IL-10 expression and M2 polarization in infiltrating Mφ (Castano et al., 2009). IL-4 and -13 activate IL-4Rα and its downstream signaling molecule STAT6 and mediate tissue repair and IL-10 immunosuppression (Zhang et al., 2017). IL-4-stimulated Mφ, not M1-stimulated Mφ, promote tubular cell proliferation (Lee et al., 2011). Locally synthesized RA, most likely produced by peritubular Mφ, represses M1 Mφ and activates RA signaling in the injured tubular epithelium, which, in turn, promotes M2 polarization, thereby reducing Mφ-dependent injury post-AKI (Chiba et al., 2016). As mentioned above, the proximal tubular mechanisms of M2 Mφ polarization are only partially understood and deserve more investigation in the future.

### M2 Mφ in the Progression of CKD

AKI is reversible as long as the cause has been eliminated and the tissue has not been structurally damaged (Chawla et al., 2011; Basile et al., 2012). So far, it is largely unknown which mechanisms determine full recovery versus subsequent CKD after AKI. For a full recovery after AKI, two conditions regarding Mφ need to be fulfilled: (1) re-transforming and/or removal of pro-fibrotic M2 Mφ; and (2) the decline in Mφ numbers to the basal level. Importantly, Mφ numbers during AKI are supposed to be strictly controlled across all stages, and uncontrolled hyper-proliferation or inadequate removal of M2 Mφ in the resolution phase of AKI may cause a non-resolving inflammation and chronic pathology as we observe in other disease areas (e.g., in muscle inflammation (Iwata et al., 2012; Baek et al., 2015; Baek et al., 2017). So far, virtually nothing is known about the fate of Mφ after the tubular repair is complete, and this needs to be investigated in the future (Huen and Cantley, 2017). Since M2 Mφ are considered to be protective in AKI, there is a growing interest to use M2 Mφ and Mφ-modulating agents as therapeutic tools to treat patients with AKI. However, it is to note that M2 Mφ are considered to be instrumental in the development of pathological fibrosis and the progression of CKD (Duffield, 2010; Anders and Ryu, 2011). Especially, several studies have identified monocyte-derived Ly6C<sup>low</sup> Mφ, which predominate over Ly6C<sup>int</sup> Mφ in the later stages of AKI, as direct or indirect contributors to interstitial fibrosis (Lin et al., 2009; Anders and Ryu, 2011; Clements et al., 2016; Lever et al., 2019; Yang et al., 2019) and as a hallmark of CKD progression post-AKI. In line with this, CX<sub>3</sub>CL1-CX<sub>3</sub>CRI-mediated survival of Ly6C<sup>low</sup> Mφ correlates with interstitial fibrosis in obstructed kidneys (Peng et al., 2015). M2 Mφ may take an important pro-fibrotic role (1) by promoting the formation of a provisional ECM (containing fibrin, fibrinogen, and fibronectin), which mediates the recruitment of fibrocytes, giving rise to myofibroblasts (= the effector cells in fibrosis, which, in turn, produce large amounts of ECM components); (2) by expressing matrix metalloproteases, some of which serve as essential drivers of fibrosis; and (3) by secreting large amounts of pro-fibrotic factors, which activate and differentiate resident fibroblasts and infiltrating fibrocytes into myofibroblasts [e.g., TGF-β1 and PDGF; vascular endothelial growth factor (VEGF), insulin-like growth factor 1 (IGF1), Galactin-3] (Vernon et al., 2010; Lech and Anders, 2013; Braga et al., 2015; Wynn and Vannella, 2016); and potentially (4) by directly transitioning into myofibroblasts to mediate interstitial fibrosis via a mechanism named "Mφ-myofibroblast transition (MMT)" (Nikolic-Paterson et al., 2014; Meng et al., 2016; Wang et al., 2016; Wang Y.Y. et al., 2017; Liang et al., 2018; Tang et al., 2018).

### ASSESSING Mφ FUNCTIONS BY DEPLETING Mφ

As discussed in detail above, Mφ are highly implicated in AKI and in the progression of CKD, and Mφ have versatile functions and are like double-edged swords being both tissue-destructive and -suppressive depending on circumstances. To successfully develop Mφ-based therapeutic approaches for AKI and its outcomes, we need to precisely understand the role of Mφ and Mφ subtypes in AKI. To assess Mφ functions in AKI, a number of studies have addressed how AKI is affected if global Mφ or individual Mφ subtypes are removed or reduced throughout different stages of AKI (Figure 1).

Acute kidney injury encompass both an injury phase and a resolution phase (Huen and Cantley, 2017). Mφ change their functional phenotype throughout different stages of AKI: Mφ are predominantly skewed toward M1 phenotypes at early stages of inflammation and toward M2 phenotypes in the resolution phase of AKI. As the phenotypic change of Mφ during AKI has been...
well characterized and is known to be a time-controlled process, the role of an individual Mφ subtype can be assessed by depleting the individual Mφ subtype by deleting the global Mφ pool at a selected time point (i.e., when the Mφ subtype predominates). A number of studies respectively pinpointed the role of M1 and M2 Mφ using various Mφ depletion strategies during and after the induction of AKI, including: (1) systemic administration of Mφ-depleting clodronate or (2) neutralizing CSF-1R antibody; and (3) DT injection in mice expressing DTR on Mφ. We note that in these studies investigators could not limit their depletion strategies to only M1 or M2 Mφ as the time-specific removal of individual Mφ subtypes only relates to the change in the relative abundance of the M1/M2 phenotypes at different time points. Of note, there may be a discrepancy between experimental AKI and its Outcomes and (3) DT injection in mice expressing DTR on Mφ. We note that in these studies investigators could not limit their depletion strategies to only M1 or M2 Mφ as the time-specific removal of individual Mφ subtypes only relates to the change in the relative abundance of the M1/M2 phenotypes at different time points. Of note, there may be a discrepancy between experimental AKI models in disease kinetics and reversibility and also a discrepancy between Mφ depletion methods. In line with this, a study showed that Mφ depletion by clodronate at a single dose effectively reduces blood monocytes, but not completely depletes tissue-resident Mφ and depleted tissue-resident Mφ are completely replenished within 72 h (Puranik et al., 2018). Other studies suggested that Mφ depletion by anti-CSF-1R primarily depletes activated resident monocytes, not affecting the numbers of pro-inflammatory monocytes (MacDonald et al., 2010) and the injury (Wynn and Vannella, 2016).

**Impact of Global Mφ Depletion on AKI and Its Outcomes**

To determine the role of global Mφ, regardless of polarization state, in AKI, studies have been performed using depletion methods based on: (1) repeated administration of Mφ-depleting agents (clodronate, small molecule CSF-1R inhibitors, neutralizing anti-CSF-1R antibodies, etc.); (2) genetic deletion of Mφ survival factors (CSF-1, IL-34 or CSF-1R deficiency) (Lenda et al., 2003; Ma et al., 2009; Baek et al., 2015). In general, a (partial) global depletion of Mφ was revealed to mitigate AKI in UUO and IRI experiments resulting in reduced tubular apoptosis (Lenda et al., 2003; Kitamoto et al., 2009; Ma et al., 2009; Baek et al., 2015) and interstitial fibrosis (Ma et al., 2009; Baek et al., 2015; Liu et al., 2018) (Table 1). In an experimental model of hypertension, the sustained depletion of global Mφ was shown to attenuate hypertensive renal injury and fibrosis as well as to lower blood pressure (Huang et al., 2018). Much to our surprise, the reduced number of M2 Mφ in II34<sup>−/−</sup> mice did not show a delay in the kidney recovery, but prevented kidney fibrosis, being clearly beneficial to the injured kidney (Baek et al., 2015). Remarkably, a UUO experiment showed that the global depletion of Mφ reduces tubular apoptosis, but does not affect interstitial fibrosis (Ma et al., 2009), but this may be due to the specificity of UUO, where the renal insult is irreversible and the suppression of the injury driving the fibrotic response is more difficult than in other models (Nikolic-Paterson et al., 2014).

When AKI was induced by cell-specific depletion of proximal tubules in Gφt1-I-DRAM mice, global depletion of Mφ led to opposite results, aggravating AKI. In this specific AKI model, global depletion of Mφ resulted in reduced survival of mice (Zhang et al., 2012), delayed functional and structural recovery from AKI and increase in interstitial fibrosis (Wang et al., 2015) (Table 1). However, it is important to mention that this AKI model does not involve a prominent Mφ infiltration as seen in other IRI models (Figure 6 in Zhang et al., 2012), indicating that the initial injury is independent of M1 Mφ and depletion of global Mφ mainly targets the resident Mφ-derived M2 pool.

Overall, these studies indicate that (partial) general depletion of Mφ is rather beneficial than harmful to the injured kidney, especially in AKI settings where Mφ infiltration and M1 Mφ are prominent features (e.g., IRI and UUO models). The significance of Mφ in tissue repair after AKI is unquestioned as Mφ are known as extremely potent phagocytes supposed to accelerate the tissue recovery by clearing debris. However, studies showed that the kidney epithelium possess its own mechanisms to self-heal, e.g., by producing autocrine factors, which mediate tubular regeneration [CSF-1 (Menke et al., 2009), TGF-β1 (Gewin et al., 2012) etc.], and Mφ may not be the only phagocytes in the injured tissue. So far, we do not know whether Mφ are indispensable in tissue repair after AKI.

**Impact of M1 Mφ Depletion on AKI and Its Outcomes**

To examine the impact of M1 Mφ on AKI and its outcomes, Mφ were depleted by injecting clodronate into mice before the induction of AKI by either uni- or bilateral IRI (Day et al., 2005; Jo et al., 2006; Vinuesa et al., 2008; Lee et al., 2011; Vinuesa et al., 2008).

**TABLE 1** | Impact of global Mφ depletion on AKI and its outcomes.

| AKI model | Depletion method | Outcomes |
|-----------|------------------|----------|
| UUO       | Clodronate (before and at day 2 and 4 of UUO) | Reduced tubular apoptosis and fibrosis (Kitamoto et al., 2009) |
| UUO       | Small molecule CSF-1R inhibitor (Fms-l; starting before UUO and 2 × daily) | Reduced tubular apoptosis; no change in fibrosis (Ma et al., 2009) |
| UUO       | CSF1 deficiency (knockout) | Reduced tubular apoptosis (Lenda et al., 2003) |
| Unilateral IRI | IL-34 deficiency (knockout) | Improved kidney function; reduced fibrosis (Baek et al., 2015) |
| Hypertension (high dose angiotensin II injections) | Clodronate (before and every 3 days till the end of the experiments) | Reduced renal injury and fibrosis; lowered blood pressure (Huang et al., 2018) |
| UUO       | Clodronate (every 2 days starting day 1 before UUO) | Reduced fibrosis (Liu et al., 2018) |
| DT-induced depletion of Ggt1-expressing proximal tubules | Clodronate or DT-induced depletion of CD11c<sup>+</sup> cells | Reduced survival (Zhang et al., 2012) |
| DT-induced depletion of Ggt1-expressing proximal tubules or unilateral IRI | Proximal tubule-specific CSF1 deficiency (conditional knockout) | Delayed functional + structural recovery from AKI; increased fibrosis (Wang et al., 2015) |
Ferenbach et al., 2012; Lu et al., 2012) or glycerol injection (Kim et al., 2014) (Table 2). All of these experiments demonstrated that reducing M1 Mφ prevents immunopathology and improves kidney function in injured kidneys. In one of these studies, the depletion of M1 Mφ paradoxically showed a reduced tubular regeneration at day 3 of bilateral IRI (Vinuesa et al., 2008); but, this may reflect that tubules were less damaged due to the depletion of M1 Mφ. Independently, M1 Mφ removal by immunotoxin (Fet et al., 2012) or neutralizing anti-CSF-1R antibody (Clements et al., 2016) prior to IRI uncovered similar findings including improved kidney function (Fet et al., 2012; Clements et al., 2016) and pathology and reduced oxidative stress (Fet et al., 2012) (Table 2). On the other hand, the reduction of M1 Mφ by clodronate injection (Lu et al., 2008) and by DT injection in Cd11b-DTR mice (± clodronate) did not show any effect on cisplatin- and ischemia-induced AKI, respectively (Ferenbach et al., 2012; Lu et al., 2012) (Table 2). Interestingly, Mφ depletion by clodronate injection improved AKI in the same IRI study (Ferenbach et al., 2012), indicating that DT-induced depletion of CD11b+ cells in Cd11b-DTR mice may have affected a larger variety of immune cells including immunosuppressive cell types. Overall, the impact of M1 Mφ depletion on AKI and its outcomes can be considered as protective in AKI.

### Impact of M2 Mφ Depletion on AKI and Its Outcomes

It may be easy to assume that the expansion of reparative M2 Mφ in the resolution phase of inflammation would be beneficial to the injured tissue, but, in reality, M2 Mφ can be both friends and foes in AKI (Braga et al., 2015). Indeed, studies focusing on evaluating the effect of M2 Mφ depletion in AKI have led to controversial results. On the one hand, depletion of M2 Mφ (e.g., by clodronate injection or DT-mediated conditional ablation of CD11b+ cells) was found to decrease kidney fibrosis (Lin et al., 2009; Kim et al., 2015; Yang et al., 2019), improve the kidney function and reduce the production of inflammatory and pro-fibrotic cytokines in some IRI and UUO experiments (Ko et al., 2008). In addition, M2 Mφ depletion starting as early as at day 1 after UUO showed an improvement of the immunopathology limiting tissue injury (Yang et al., 2019) (Table 3). Notably, renal fibrosis was found to be reduced in all experiments where M2 Mφ depletion improves the renal pathology after AKI, indicating that the most undesirable feature of M2 Mφ in Mφ-based therapeutic approaches for AKI and CKD is the capability to promote renal fibrosis. Some IRI and septic AKI experiments, on the other hand, led to completely opposite results suggesting that M2 Mφ fibrosis. Some IRI and septic AKI experiments, on the other hand, led to completely opposite results suggesting that M2 Mφ fibrosis.

| Impact of M2 Mφ depletion on AKI and its outcomes: beneficial |
|---|---|---|
| Bilateral IRI | Clodronate (before IRI) | Reduced tubular necrosis, apoptosis; reduced inflammation (Day et al., 2005; Jo et al., 2008) |
| Unilateral IRI plus contralatral nephrectomy | Clodronate (before IRI) | Reduced tubular injury; improved kidney function; but also reduced tubular regeneration (at day 3 of IRI) (Vinuesa et al., 2008) |
| Unilateral IRI | Clodronate (before IRI) | Reduced tubular injury; improved kidney function (Fet et al., 2012) |
| Unilateral IRI plus contralateral nephrectomy | Immunoa toxin H22(scFv)-ETA (at 6 h of IRI) | Improved histology; less oxidative stress; improved kidney function (Fet et al., 2012) |
| Glycerol injection | Clodronate (before injection) | Reduced tubular apoptosis; reduced inflammation (Kim et al., 2014) |

| Impact of M2 Mφ depletion on AKI and its outcomes: none |
|---|---|---|
| Cisplatin injection | Clodronate (before + at day 1) | None (Lu et al., 2008) |
| Unilateral IRI | Conditional (DT/DTR) ablation of CD11b+ cells ± clodronate (before IRI) | None (Ferenbach et al., 2012; Lu et al., 2012) |

which was contrary to the observations previously mentioned (Menke et al., 2009). In addition, DT-mediated depletion of CD169+ cells, which represent tissue-resident M2 Mφ, markedly worsened the kidney injury and increased the lethality in mice after IRI, which, but, could be rescued by the adoptive transfer of Ly6C− monocytes (Karasawa et al., 2015). Notwithstanding all of above, there was also a study showing that M2 Mφ depletion (by conditional ablation in Cd11b- or Cd11c-DTR) does not have any impact on the development of fibrosis after unilateral IRI (Kim et al., 2015) (Table 3). In summary, the impact of M2 Mφ depletion on AKI and its outcomes was not consistent throughout the experiments, illustrating that M2 Mφ can be both beneficial and harmful to the injured kidney. These controversial results from AKI studies focusing on elucidating the role of M2 Mφ corroborate the dual nature of M2 Mφ. It is interesting to note that M2 Mφ can be rather disturbing than useful in the recovery process after AKI depending on the conditions given.

### Mφ-BASED THERAPEUTIC STRATEGIES

Mφ are instrumental in maintaining immune homeostasis and mediating inflammation. Therefore, modulation of Mφ functions is widely considered as a promising approach for various kidney
Table 3 Impact of M2 Mφ depletion on AKI and its outcomes.

| AKI model | Depletion method | Outcomes |
|-----------|------------------|----------|
| Unilateral IRI plus contralateral nephrectomy | Clodronate (starting on day 3) | Improved kidney function; reduced production of inflammatory and pro-fibrotic cytokines (Ko et al., 2008) |
| UUO | Conditional (DT/DTR) ablation of CD11b+ cells (at day 7–9) | Reduced fibrosis (Lin et al., 2009) |
| Unilateral IRI | Clodronate (starting on day 3) | Reduced fibrosis (Kim et al., 2015) |
| Unilateral IRI | Clodronate (starting on day 1) | Improved histology; reduced kidney injury; reduced fibrosis (Yang et al., 2019) |

Impact of M2 Mφ depletion on AKI and its outcomes: beneficial

| AKI model | Depletion method | Outcomes |
|-----------|------------------|----------|
| Bilateral IRI | Clodronate (at day 6) | Increased tubular damage; increased oxidative stress; delayed recovery from AKI (Jiang et al., 2008) |
| Unilateral IRI plus CSF-1 injection | Clodronate (starting on day 1–3) | Increased fibrosis; decreased kidney function; increased apoptosis (Menke et al., 2009) |
| Unilateral IRI plus contralateral nephrectomy | Clodronate (at day 2 and 3) | Less improvement in glomerular filtration; impaired tubular regeneration (Lee et al., 2011) |
| Unilateral IRI ± contralateral nephrectomy | Conditional (DT/DTR) ablation of CD169+ cells (24–36 h before IRI) | Lethality, failed kidney function, increased inflammation (Karasawa et al., 2015) |
| Bilateral IRI | Neutralizing anti-CSF-1R antibody (at day 1–3) | Increased apoptosis (Clements et al., 2016) |
| CLP | Clodronate | Worsening AKI; decreased kidney function (Li et al., 2018) |

Impact of M2 Mφ depletion on AKI and its outcomes: harmful

| AKI model | Depletion method | Outcomes |
|-----------|------------------|----------|
| Unilateral IRI | Conditional (DT/DTR) ablation of CD11b+ or CD11c+ cells (starting on day 3) | No change in fibrosis (Kim et al., 2015) |

Conclusion and Outlook

This review has provided insights into the net effect of versatile Mφ functions in AKI by Mφ removal studies (Figure 1). Interestingly, several studies suggest that the (partial) depletion of global Mφ in AKI can be beneficial to the injury kidney. In addition, this review has assessed the current literature on the impact of the depletion of individual Mφ subtypes on AKI and its outcomes and found that M1 Mφ depletion has been shown to be generally protective against AKI, whereas M2 Mφ depletion has led to controversial results.

How can we translate findings from animal AKI models into clinical practice? M1 Mφ instantly enter the tissue within an hour after AKI and phenotypically switch to M2 Mφ within a couple of days. In most AKI cases, the onset cannot be predicted (e.g., unless patients are scheduled for a kidney transplant or other relevant surgery) and precedes the diagnose. Thus, therapeutic intervention via targeting of M1 Mφ can resolve inflammation, there is a growing interest to use M2 Mφ and Mφ-modulating agents as therapeutic tools to treat patients with AKI (Chen et al., 2019); however, we may not underestimate that M2 Mφ can contribute to interstitial fibrosis and facilitate the AKI-to-CKD transition. Overall, M2 Mφ act as double-edged swords being both beneficial and harmful to the inflamed kidney tissue (Braga et al., 2015), and the dual nature of M2 Mφ is well recapitulated in the results from M2 Mφ depletion.
studies. As uncontrolled hyper-proliferation or inadequate removal of Mφ in the resolution phase of inflammation can cause chronic inflammation and eventual organ failure, we need to simultaneously consider two avenues, when developing therapeutic approaches targeting Mφ, including: (1) modulation of Mφ activation and functions and (2) removal of excess Mφ. Previous studies investigating the role of Mφ in AKI mostly focused on the mechanism of Mφ survival, proliferation and polarization, we do not understand by which mechanisms Mφ disappear in the resolution phase of inflammation. Future studies need to investigate the fate of individual Mφ subtypes after the tissue repair is completed.

REFERENCES

Alikhan, M. A., Jones, C. V., Williams, T. M., Beckhouse, A. G., Fletcher, A. L., Kett, M. M., et al. (2011). Colony-stimulating factor-1 promotes kidney growth and repair via alteration of macrophage responses. Am. J. Pathol. 179, 1243–1256. doi: 10.1016/j.ajpath.2011.05.037

Andres-Hernando, A., Okamura, K., Bhargava, R., Kiekhaefer, C. M., Soranno, D., Kirkbride-Romeo, L. A., et al. (2017). Circulating IL-6 upregulates IL-10 production in splenic CD4+ T cells and limits acute kidney injury-induced lung inflammation. Kidney Int. 91, 1057–1069. doi: 10.1016/j.kint.2016.12.014

Anders, H. J., and Ryu, M. (2011). Renal microenvironments and macrophage phenotypes determine progression or resolution of renal inflammation and fibrosis. Kidney Int. 80, 915–925. doi: 10.1038/ki.2011.217

Baek, J. H., Gomez, I. G., Wada, Y., Roach, A., Mahad, D., and Duffield, J. S. (2018). Arai, S., Kitada, K., Yamazaki, T., Takai, R., Zhang, X., Tsugawa, Y., et al. (2016). Apoptosis inhibitor of macrophage protein enhances intraluminal debris clearance and ameliorates acute kidney injury in mice. Nat. Med. 22, 183–193. doi: 10.1038/nm.4012

Baek, J. H., Gomeza, J. I., Wada, Y., Roach, A., Mahad, D., and Duffield, J. S. (2018). Deletion of the mitochondrial complex-IV cofactor heme a/afarnesytransferase causes focal segmental glomerulosclerosis and interferon response. Am. J. Pathol. 188, 2745–2762. doi: 10.1016/j.ajpath.2018.08.018

Baek, J. H., Many, G. M., Everson, F. J., and Kelley, V. R. (2017). Dysferlinopathy promotes an intramuscle expansion of macrophages with a cyto-destructive phenotype. Am. J. Pathol. 187, 1245–1257. doi: 10.1016/j.ajpath.2017.02.011

Baek, J. H., Zeng, R., Weinmann-Menze, J., Valerius, M. T., Wada, Y., Ajay, A. K., et al. (2015). IL-34 mediates acute kidney injury and worsens subsequent chronic kidney disease. J. Clin. Invest. 125, 3198–3214. doi: 10.1172/JCI81166

Bao, Y. W., Yuan, Y., Chen, J. H., and Lin, W. Q. (2018). Kidney disease models: tools to identify mechanisms and potential therapeutic targets. Zool. Res. 39, 72–86. doi: 10.24272/zrr.2019.081273.055

Barrera-Chimal, J., Estrella, G. R., Lechner, S. M., Giraud, S., El Moghrabi, S., Kaaki, M., et al. (2016). The proximal tubule is the primary target of injury and fibrosis. Kidney Int. 89, 1344–1355. doi: 10.1016/j.kint.2017.12.016

Basile, D. P., Anderson, M. D., and Sutton, T. A. (2012). Pathophysiology of acute kidney injury. Compr. Physiol. 2, 1503–1533. doi: 10.1002/cphy.c110041

Braga, T. T., Agudelo, J. S., and Camara, N. O. (2015). Macrophages during the fibrotic process: M2 as friend and foe. Front. Immunol. 6:602. doi: 10.3389/fimmu.2015.00602

Bucalou, I. D., Kirchner, H. L., Norfolk, E. R., Hartle, J. E. II, and Perkins, R. M. (2012). Increased risk of death and de novo chronic kidney disease following reversible acute kidney injury. Kidney Int. 81, 477–485. doi: 10.1038/ki.2011.405

Bussolati, B., Bruno, S., Grange, C., Buttiglieri, S., Deregibus, M. C., Cantino, D., et al. (2005). Isolation of renal progenitor cells from adult human kidney. Am. J. Pathol. 166, 545–555. doi: 10.1016/S0002-9440(10)62276-62276

Cao, Q., Wang, C., Zheng, D., Wang, Y., Lee, V. W., Wang, Y. M., et al. (2011). IL-25 induces M2 macrophages and reduces renal injury in proteinuric kidney disease. J. Am. Soc. Nephrol. 22, 1229–1239. doi: 10.1681/ASN.2010070695

Cao, Q., Wang, Y., Niu, Z., Wang, C., Wang, R., Zhang, Z., et al. (2018). Potential role of tissue-resident Type 2 innate lymphoid cells by IL-33 to prevent renal ischemia-reperfusion injury. J. Am. Soc. Nephrol. 29, 961–976. doi: 10.1681/ASN.2017070774

Cao, Q., Wang, Y., Zheng, D., Sun, Y., Wang, Y., Lee, V. W., et al. (2010). IL-10/Th2-beta-modified macrophages induce regulatory T cells and protect against adriamycin nephrosis. J. Am. Soc. Nephrol. 21, 933–942. doi: 10.1681/ASN.2009060592

Castano, A. P., Lin, S. L., Surowy, T., Nowlin, B. T., Turlapati, S. A., Patel, T., et al. (2009). Serum amyloid P inhibits fibrosis through Fc gamma R-dependent monocyte-macrophage regulation. Kidney Int. 72, 21, 1270–1274. doi: 10.1681/ASN.2010030233

Chawla, L. S., Amurd, R. L., Ammodeo, S., Kimmel, P. L., and Palant, C. E. (2011). The severity of acute kidney injury predicts progression to chronic kidney disease. Kidney Int. 79, 1361–1369. doi: 10.1038/kid.2011.42

Chawla, L. S., Eggers, P. W., Star, R. A., and Kimmel, P. L. (2014). Acute kidney injury and chronic kidney disease as interconnected syndromes. N. Engl. J. Med. 371, 58–66. doi: 10.1056/NEJMra1214243

Chen, L., Sha, M. L., Li, D., Zhu, Y. P., Wang, X. J., Jiang, C. Y., et al. (2017). Relaxin abrogates renal interstitial fibrosis by regulating macrophage polarization via inhibition of Toll-like receptor 4 signaling. Oncotarget 8, 21044–21053. doi: 10.18632/oncotarget.15483

Chevalier, R. L. (2016). The proximal tubule is the primary target of injury and progression of kidney disease: role of the glomerulotubular junction. Am. J. Physiol. Renal. Physiol. 311, F415–F416. doi: 10.1152/ajphen.00164.2016

Chiba, T., Skrypnik, N. I., Skvarca, L. B., Penchev, R., Zhang, K. X., Rochon, E. R., et al. (2016). Retinoic acid signaling coordinates macrophage-dependent injury and repair after AKI. J. Am. Soc. Nephrol. 27, 495–508. doi: 10.1681/ASN.2014111108

Chou, Y. H., Huang, T. M., and Chu, T. S. (2017). Novel insights into acute kidney injury-chronic kidney disease continuum and the role of renin-angiotensin system. J. Formos. Med. Assoc. 116, 652–659. doi: 10.1016/j.jfma.2017.04.026

Chung, S., Overstreet, J. M., Li, Y., Wang, Y., Niu, A., Wang, S., et al. (2018). TGF-beta promotes fibrosis after severe acute kidney injury by enhancing renal macrophage infiltration. JCI Insight 3:42363. doi: 10.1172/jci.insight.42363

Clements, M., Gershonovich, M., Chaber, C., Campos-Rivera, J., Du, P., Zhang, M., et al. (2016). Differential Ly6C expression after renal ischemia-reperfusion identifies unique macrophage populations. J. Am. Soc. Nephrol. 27, 159–170. doi: 10.1681/ASN.2014111138

Day, Y. J., Huang, L., Ye, H., Linden, J., and Okusa, M. D. (2005). Renal ischemia-reperfusion injury and adenosine 2A receptor-mediated tissue protection: role of macrophages. Am. J. Physiol. Renal. Physiol. 288, F722–F731. doi: 10.1152/ajprenal.00378.2004

AUTHOR CONTRIBUTIONS

J-HB conceptualized and wrote the manuscript.

FUNDING

The author declares that this study received funding from the Biogen. Biogen is paying for the publication fee of this review manuscript. Biogen has no role in the study design, data collection and analysis, decision to publish, or preparation of this manuscript.
Leaf, I. A., Nakagawa, S., Johnson, B. G., Cha, J. J., Mittelsteadt, K., Guckian, K. M., Baek, V., Versatile M., Lech, M., and Anders, H. J. (2013). Macrophages and fibrosis: how resident and inflamed macrophage phenotypes contribute to kidney injury and repair. *Front. Immunol.* 4, 2385. doi: 10.3389/fimmu.2013.00238

Lyu, L., Faubel, S., He, Z., Andres Hernando, A., Jani, A., Keel, R., et al. (2012). Depletion of macrophages and dendritic cells in ischemic acute kidney injury. *Am. J. Physiol. Renal Physiol.* 296, F177–F185. doi: 10.1152/ajprenal.90489.2008

MacDonald, K. P., Palmer, J. S., Cronau, S., Seppanen, E., Olver, S., Raffelt, N. C., et al. (2010). An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation. *Blood* 116, 3955–3963. doi: 10.1182/blood-2010-02-266296

Martinez, F. O., Helming, L., and Gordon, S. (2009). Alternative activation of macrophages: an immunologic functional perspective. *Annu. Rev. Immunol.* 27, 451–483. doi: 10.1146/annurev.immuno.020908.132532

Mass, E., Ballesteros, I., Farlik, M., Halbritter, F., Gunther, P., Crozet, L., et al. (2016). Specification of tissue-resident macrophages during organogenesis. *Science* 353, 842–852. doi: 10.1126/science.aaf4238

McDonald, B., Pittman, K., Menezes, G. B., Hirota, S. A., Slaba, I., Waterhouse, C. C., et al. (2010). Intravascular danger signals guide neutrophils to sites of sterile inflammation. *Science* 330, 362–366. doi: 10.1126/science.1195491

Meng, X. M., Wang, S., Huang, X. R., Yang, C., Xiao, J., Zhang, Y., et al. (2016). Inflammatory macrophages can transdifferentiate into myofibroblasts during renal fibrosis. *Cell Death Dis.* 7:e2495. doi: 10.1038/cddis.2016.402

Menke, J., Iwata, Y., Rabacal, W. A., Basu, R., Yeung, Y. G., Humphreys, B. D., et al. (2009). Csf-1 signals directly to renal tubular epithelial cells to mediate repair in mice. *J. Clin. Invest.* 119, 2330–2342. doi: 10.1172/JCI39087

Meshikhab, S., Gower, M. W., Dekaban, G. A., and Kim, S. O. (2014). G-CSF preferentially supports the generation of gut-homing Gr1-high macrophages in M-CSF-treated bone marrow cells. *J. Leukoc. Biol.* 96, 549–561. doi: 10.1172/jlb.0314-1721

Mills, C. D., Kincaid, K., Alt, J. M., Heilmann, M. J., and Hill, A. M. (2000). M-1/M-2 macrophages and the Th1/Th2 paradigm. *J. Immunol.* 164, 6616–6617. doi: 10.4049/jimmunol.164.12.6616

Murray, P. J., Allen, J. E., Biswas, S. K., Fisher, E. A., Gilroy, D. W., Goedert, M. J., et al. (2014). Macrophage activation and polarization: nomenclature and experimental guidelines. *Immunity* 41, 14–20. doi: 10.1016/j.immuni.2014.06.008

Murray, P. J., and Wynn, T. A. (2011). Protective and pathogenic functions of macrophage subsets. *Nat. Rev. Immunol.* 11, 723–737. doi: 10.1038/nri3172

Nandi, S., Ciocie, M., Yeung, Y. G., Nieves, E., Tesfa, L., Lin, H., et al. (2013). Receptor-type protein-tyrosine phosphatase zeta is a functional receptor for interleukin-34. *J. Biol. Chem.* 288, 21972–21986. doi: 10.1074/jbc.M112.442731

Nikolic-Paterson, D. J., and Atkins, R. C. (2001). The role of macrophages in glomerulonephritis. *Nephrol. Dial. Transplant.* 16(Suppl. 5), 3–7. doi: 10.1093/ndt/16.suppl_5.3

Nikolic-Paterson, D. J., Wang, S., and Lan, H. Y. (2014). Macrophages promote renal fibrosis through direct and indirect mechanisms. *Kidney Int. Suppl.* 4, 34–38. doi: 10.1038/kisup.2014.7

Oh, D. J., Dursun, B., He, Z., Lu, L., Hoke, T. S., Ljubanovic, D., et al. (2008). Fractalkine receptor (CX3CR1) inhibition is protective against ischemic acute renal failure in mice. *Am. J. Physiol. Renal Physiol.* 294, F264–F271. doi: 10.1152/ajprenal.00162.2011

Ortiz, A., Sanchez-Nino, M. D., Izquierdo, M. C., Martin-Cleary, C., Garcia-Bermejo, L., Moreno, J. A., et al. (2015). Translational value of animal models

nu-SNF1 function and regulation. *Science* 355, 2232–2237. doi: 10.1126/science.aaf4238
of kidney failure. *Eur. J. Pharmacol.* 759, 205–220. doi: 10.1016/j.ejphar.2015.03.026

Peng, X., Zhang, J., Xiao, Z., Dong, Y., and Du, J. (2015). CX3CL1-CX3CR1 interaction increases the population of Ly6C(−)/CX3CR1(+) macrophages contributing to unilateral ureteral obstruction-induced fibrosis. *J. Immunol.* 195, 2797–2805. doi: 10.4049/jimmunol.1403209

Perry, H. M., and Okusa, M. D. (2015). Driving change: kidney proximal tubule CSF-1 polarizes macrophages. *Kidney Int. 88, 1219–1221.* doi: 10.1038/ki.2015.324

Peyraud, F., Cousin, S., and Italiano, A. (2017). CSF-1R inhibitor development: current clinical status. *Curr. Oncol. Rep.* 19:70. doi: 10.1007/s11912-017-0634-631

Puranki, A. S., Leaf, I. A., Jensen, M. A., Hedayat, A. F., Saad, A., Kim, K. W., et al. (2018). Kidney-resident macrophages promote a proangiogenic environment in the normal and chronically ischemic mouse kidney. *Sci. Rep.* 8:13948. doi: 10.1038/s41598-018-31887-31884

Rabb, H., Griffin, M. D., McKay, D. B., Swaminathan, S., Pickkers, P., Rosner, M. H., et al. (2016). Inflammation in AKI: current understanding, key questions, and knowledge gaps. *J. Am. Soc. Nephrol.* 27, 371–379. doi: 10.1681/ASN.2015030261

Raggi, F., Pelassa, S., Pierobon, D., Penco, F., Gattorno, M., Novelli, F., et al. (2017). Regulation of human macrophage M1-M2 polarization balance by hypoxia and the triggering receptor expressed on myeloid cells-1. *Front. Immunol.* 8:1097. doi: 10.3389/fimmu.2017.01097

Ramesh, G., and Ranganathan, P. (2014). Mouse models and methods for studying human disease, acute kidney injury (AKI). *Methods Mol. Biol.* 1194, 421–436. doi: 10.1007/978-1-4939-1215-5_24

Ranganathan, P. V., Jayakumar, C., and Ramesh, G. (2013). Netrin-1-treated macrophages protect the kidney against ischemia-reperfusion injury and suppress inflammation by inducing M2 polarization. *Am. J. Physiol. Renal Physiol.* 304, F948–F957. doi: 10.1152/ajprenal.00580.2012

Reeves, W. B., Kwon, O., and Ramesh, G. (2008). Netrin-1 and kidney injury. II. Netrin-1 is an early biomarker of acute kidney injury. *Am. J. Physiol. Renal Physiol.* 294, F731–F738. doi: 10.1152/ajprenal.00507.2007

Rota, C., Morici, M., Cerullo, D., Introna, M., Colpani, O., Corna, D., et al. (2018). Therapeutic potential of stromal cells of non-renal or renal origin in experimental chronic kidney disease. *Stem Cell Res. Ther.* 9:220. doi: 10.1186/s13287-018-0960-968

Schmidt, I. M., Hall, I. E., Kale, S., Lee, C. H., Lee, Y., et al. (2013). Chitinase-like protein Brp-39/YKL-40 modulates the renal response to ischemic inflammatory renal disease. *J. Am. Soc. Nephrol.* 24, 309–319. doi: 10.1681/ASN.2012060579

Schulz, C., Gomez Perdiguero, E., Chorro, L., Szabo-Rogers, H., Cagnard, N., Kierdorf, K., et al. (2012). A lineage of myeloid cells independent of Myb and hemopoietic stem cells. *Science* 336, 86–90. doi: 10.1126/science.1219179

Sere, K., Baek, J. H., Ober-Blobaum, J., Muller-Newen, G., Tacke, F., Yokota, Y., et al. (2012). Two distinct types of langerhans cells populate the skin during regeneration, and fibrosis. *Eur. J. Pharmacol.* 72, 290–299. doi: 10.1016/j.ejphar.2015.03.026

Takaori, K., Nakamura, J., Yamamoto, S., Nakata, H., Sato, Y., Takase, M., et al. (2016). Severity and frequency of proximal tubule injury determines renal prognosis. *J. Am. Soc. Nephrol.* 27, 2393–2406. doi: 10.1681/ASN.2015060647

Tanaka, S., Tanaka, T., and Nangaku, M. (2014). Hypoxia as a key player in the AKI-to-CKD transition. *Am. J. Physiol. Renal Physiol.* 307, F1187–F1195. doi: 10.1152/ajprenal.00245.2014

Tang, P. M., Zhou, S., Li, C. J., Liao, J., Xiao, J., Wang, Q. M., et al. (2018). The proto-oncogene tyrosine protein kinase Sre is essential for macrophage-myofibroblast transition during renal scarring. *Kidney Int.* 93, 173–187. doi: 10.1016/j.kint.2017.07.026
Yang, Q., Wang, Y., Pei, G., Deng, X., Jiang, H., Wu, J., et al. (2019). Bone marrow-derived Ly6C(-) macrophages promote ischemia-induced chronic kidney disease. Cell Death Dis. 10:291. doi: 10.1038/s41419-019-1531-1533

Zhang, M. Z., Wang, X., Wang, Y., Niu, A., Wang, S., Zou, C., et al. (2017). IL-4/IL-13-mediated polarization of renal macrophages/dendritic cells to an M2a phenotype is essential for recovery from acute kidney injury. Kidney Int. 91, 375–386. doi: 10.1016/j.kint.2016.08.020

Zhang, M. Z., Yao, B., Yang, S., Jiang, L., Wang, S., Fan, X., et al. (2012). CSF-1 signaling mediates recovery from acute kidney injury. J. Clin. Invest. 122, 4519–4532. doi: 10.1172/JCI60363

Zhang, W. R., Garg, A. X., Coca, S. G., Devereaux, P. J., Eikelboom, J., Kavsak, P., et al. (2015). Plasma IL-6 and IL-10 concentrations predict AKI and long-term mortality in adults after cardiac surgery. J. Am. Soc. Nephrol. 26, 3123–3132. doi: 10.1681/ASN.2014080764

Zuk, A., and Bonventre, J. V. (2016). Acute kidney injury. Annu. Rev. Med. 67, 293–307. doi: 10.1146/annurev-med-050214-13407

Zuk, A., and Bonventre, J. V. (2019). Recent advances in acute kidney injury and its consequences and impact on chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 28, 397–405. doi: 10.1097/MNH.0000000000000504

Conflict of Interest Statement: J-HB is an employee of Biogen.